Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device
First Claim
1. A biocompatible drug release matrix for a medical device comprising:
- a biocompatible polymer matrix; and
a drug incorporated into the biocompatible polymer matrix, wherein the biocompatible polymer matrix is co-solubilized with the drug in a solvent to form a solution and the solvent is evaporated from the solution.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention is an apparatus and a method for delivery of mitomycin through an eluting biocompatible implantable medical device. A biocompatible drug release matrix comprises a biocompatible drug release matrix and a drug incorporated into the biocompatible drug release matrix. The drug has antibiotic and anti-proliferative properties and is an analogue related to the quinone-containing alkylating agents of a mitomycin family. The drug is initially released from the biocompatible drug release matrix at a faster rate followed by a release at a slower rate. The drug release rate maintains tissue level concentrations of the drug for at least two weeks after implantation of the medical device. The present invention provides a coating for a vascular prosthesis that elutes the drug at a controlled rate to inhibit proliferation of smooth muscle cells causing restenosis.
-
Citations
104 Claims
-
1. A biocompatible drug release matrix for a medical device comprising:
-
a biocompatible polymer matrix; and
a drug incorporated into the biocompatible polymer matrix, wherein the biocompatible polymer matrix is co-solubilized with the drug in a solvent to form a solution and the solvent is evaporated from the solution. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
-
-
16. A biocompatible implantable medical device for delivering a drug to a treatment area in a vasculature of a body comprising:
-
a tubular body having a proximal end, a distal end and a longitudinal axis therebetween;
a proximal end band at the proximal end of the tubular body, a distal end band at the distal end of the tubular body and a plurality of intermediate bands between the proximal end band and the distal end band;
a plurality of circumferential rows of links engaging the proximal end band, the plurality of intermediate bands and the distal end band to form the tubular body; and
an elution layer comprising a biocompatible drug release matrix applied to the surface of the biocompatible implantable medical device having a biocompatible polymer matrix solubilized with the drug in a solvent to form a solution and the solvent is evaporated, wherein the drug is released from the biocompatible drug release matrix after implantation of the biocompatible implantable medical device to prevent restenosis. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)
-
-
41. A method of inhibiting the growth of smooth muscle cells to inhibit restenosis comprising:
-
providing a biocompatible implantable medical device;
preparing a biocompatible polymer matrix;
co-solubilizing the biocompatible polymer matrix with a drug in a solvent to form a biocompatible drug release matrix;
applying the biocompatible drug release matrix to the biocompatible implantable medical device to form an elution layer of the biocompatible drug release matrix on the biocompatible implantable medical device;
allowing the solvent to evaporate; and
implanting the biocompatible implantable medical device into a vasculature of a body. - View Dependent Claims (42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)
-
-
71. A method of inhibiting the proliferation of smooth muscle cells after a stent implantation comprising:
-
providing a stent;
preparing a biocompatible polymer matrix;
co-solubilizing the biocompatible polymer matrix with a drug in a solvent to form a solution;
applying the solution onto the stent to form an elution layer of a biocompatible drug release matrix on the biocompatible implantable medical device;
allowing the solvent to evaporate;
engaging the stent onto a balloon of a balloon catheter;
delivering the balloon catheter with the stent engaged onto the balloon of the balloon catheter into a vasculature of a body to a treatment site; and
inflating the balloon of the balloon catheter to increase a diameter of the stent to implant the stent. - View Dependent Claims (72, 73, 74, 75, 76, 77)
-
-
78. A biocompatible drug release matrix for a medical device comprising:
-
a biocompatible drug eluting matrix; and
a drug incorporated into the biocompatible drug eluting matrix, wherein the drug is an analogue related to the quinone-containing alkylating agents of a mitomycin family. - View Dependent Claims (79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)
-
-
96. A method of inhibiting restenosis comprising:
-
providing a medical device;
applying a biocompatible drug eluting matrix comprising a biocompatible polymer matrix incorporating an analogue related to the quinone-containing alkylating agents of a mitomycin family to the medical device; and
implanting the biocompatible implantable medical device into a vessel to elute the analogue related to the quinone-containing alkylating agents of a mitomycin family. - View Dependent Claims (97, 98, 99, 100, 101, 102, 103, 104)
-
Specification